EGFR突变与非小细胞肺癌放射治疗进展 Translated title: Epidermal Growth Factor Receptor Mutations and Radiotherapy in Non-small Cell Lung Cancer

Abstract

放射治疗在肺癌治疗中占据重要地位。表皮生长因子受体（epidermal growth factor receptor, EGFR）突变是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）使用酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）治疗有效的预测因子。同时， EGFR突变型NSCLC对放射治疗敏感，这可能与突变型 EGFR不能有效进行核转位而导致DNA损伤修复功能受损相关。初步研究显示EGFR酪氨酸激酶抑制剂在NSCLC放射治疗中具有一定的放疗增敏作用，但其在 EGFR突变型NSCLC放疗中的疗效尚不确切。 EGFR突变与NSCLC的放疗效应机制及生存预后的关系值得进一步研究。

Translated abstract

Radiotherapy plays a pivotal role in the treatment for lung cancer. Epidermal growth factor receptor ( EGFR) mutation in non-small cell lung cancer (NSCLC) which predicts tyrosine kinase inhibitor (TKI) treatment response may also has effect on radiation response. NSCLC harboring kinase-domain mutations in EGFR exhibits enhanced radio-sensitivity due to dramatically diminished capacity to resolve radiation-induced DSBs (DNA double-strand breaks) associating with the inefficiency of EGFR nuclear translocation. Recently, several preliminary clinical studies show certain efficacy of concurrent EGFR tyrosine kinase inhibitors and radiotherapy. However its further response in EGFR-mutated NSCLC is unclear. The correlation between EGFR mutation genotype and the radiotherapy response and clinical outcome is worthy of further study.